Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by prophetoffactzon Apr 29, 2024 11:31am
82 Views
Post# 36012699

RE:RE:RE:New Press Release - Ceapro Inc. Reports 2023 Financial Results and Operational Highlights

RE:RE:RE:New Press Release - Ceapro Inc. Reports 2023 Financial Results and Operational Highlights"- Note: Inventory went up by 41% year-on-year from $3.8M to $5.3M AND
Cash dropped by 36% from $13.8M to $8.8M"

The major client, which had represented 50% of CZO's base business, began reordering in Q1 2024 as noted in the Feb. news release. Having inventory on hand for this major client is a positive and should help to materially reduce inventory moving forward.
<< Previous
Bullboard Posts
Next >>